Diagnostic and Prognostic Significance of microRNA-208a in Acute Myocardial Infarction

Abstract

Objective. To determine the prognostic and diagnostic significance of microRNA-208a (miR-208a) in acute myocardial infarction (AMI). Methods. Totally, 84 AMI patients hospitalized in our hospital between Jan. 2019 and Feb. 2021 were enrolled as the patient group (Pat group), and 50 healthy individuals over same time span as the control group (Con group). qRT-PCR assay was carried out to quantify serum miR-208a in the patients and receiver-operating characteristic (ROC) curves for analysing its diagnostic value in AMI patients and its predictive value in clinical efficacy and adverse events in the patients after therapy. The changes of miR-208a and clinical indexes ((lactate dehydrogenase (LDH), creatine kinase (CK) as well as Creatine kinase-MB (CK-MB)) in the patients before and after therapy were evaluated. Pearson’s test was adopted to analyse the associations of miR-208a with clinical indexes. Additionally, the target genes of miR-208a were forecasted. Results. The patient group showed a higher miR-208a level than the control group ( p < 0.05 ), and the area under the curve (AUC) of miR-208a in diagnosing AMI was >0.9. After therapy, patients presented notable decreases in serum miR-208a, LDH, CK, and CK-MB (all p < 0.05 ). Serum miR-208a presented positive associations with LDH, CK, as well as CK-MB both before and after therapy (all p < 0.05 ). Before therapy, the ineffective group presented a higher miR-208a level than the effective group ( p < 0.05 ), and miR-208a had an AUC of 0.784 in forecasting efficacy. Additionally, the group with adverse events presented a higher miR-208a level than the group without them before therapy ( p < 0.05 ), and miR-208a had an AUC of 0.713 in forecasting adverse events. According to enrichment analysis, the target genes of miR-208a were bound up with signal pathways of cellular senescence, MTOR and Wnt. Conclusion. With high expression in AMI cases, miR-208a is a promising potential biomarker for diagnosis and prognosis forecasting of AMI.

Advances in the study of exosomes derived from mesenchymal stem cells and cardiac cells for the treatment of myocardial infarction

“…This characteristic could potentially make them useful as biomarkers for timely diagnosis, staging, and monitoring of disease during treatment. For instance, multiple studies have shown that miR-208a in exosomes released from injured cardiomyocytes after MI has the advantages of strong myocardial specificity, high sensitivity and strong stability, and is positively correlated with the indexes of myocardial function before and after therapy [112,[179][180][181]. The functional diversity of exosomes secreted by cardiac cells also suggests that these various cell types should be further explored as potential sources of therapeutic exosomes.…”

Advances in research on biomarkers associated with acute myocardial infarction: A review

“…This finding suggests the potential of miR-208a as a promising biomarker for the diagnosis and prediction of AMI, thus positioning it as a highly valuable biomarker in clinical settings. [ 68 ] Multiple studies have shown that circulating miR-208 is a reliable biomarker for diagnosing STEMI and NSTEMI. Moreover, miR-208 can distinguish patients presenting with AMI symptoms, such as chest pain, from healthy controls.…”